financetom
Business
financetom
/
Business
/
--Palantir Technologies Guides For Full Year 2024 Revenue of $2.742-$2.75 Billion, vs CIQ Analyst Consensus of $2.7 Billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Palantir Technologies Guides For Full Year 2024 Revenue of $2.742-$2.75 Billion, vs CIQ Analyst Consensus of $2.7 Billion
Aug 5, 2024 1:58 PM

04:08 PM EDT, 08/05/2024 (MT Newswires) --

Price: 28.00, Change: +3.90, Percent Change: +16.18

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China's CATL sees slowest profit growth in six years
China's CATL sees slowest profit growth in six years
Mar 14, 2025
BEIJING (Reuters) - CATL reported 15% growth in 2024 net profit, the slowest pace in six years, as a prolonged price war in China's electric vehicle market put pressure on the Chinese EV battery giant. Net profit was up 15% last year to 50.7 billion yuan ($7.01 billion), versus its forecast of 11.1-20.1%, according to a stock filing on Friday....
Tesla in Letter to US Trade Representative's Office Warns About Trade Policy Impacts on Domestic Exporters
Tesla in Letter to US Trade Representative's Office Warns About Trade Policy Impacts on Domestic Exporters
Mar 14, 2025
08:30 AM EDT, 03/14/2025 (MT Newswires) -- Tesla (TSLA) in a letter to the US Trade Representative's Office said the US exporters are inherently exposed to disproportionate impacts when other countries retaliate against US trade actions. In the letter, dated Tuesday, Tesla urged the government to consider the downstream effects of trade measures aimed at addressing unfair trade practices. Tesla...
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation
Mar 14, 2025
08:38 AM EDT, 03/14/2025 (MT Newswires) -- Korro Bio ( KRRO ) said Friday that the US Food and Drug Administration has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of alpha-1 antitrypsin deficiency, or AATD. AATD is a genetic disorder that can cause pulmonary emphysema and/or hepatic cirrhosis, Korro Bio ( KRRO ) said. Korro...
Turtle Beach's PDP Acquisition Seen Driving Over $400 Million in Revenue in 2025, Wedbush Says
Turtle Beach's PDP Acquisition Seen Driving Over $400 Million in Revenue in 2025, Wedbush Says
Mar 14, 2025
08:33 AM EDT, 03/14/2025 (MT Newswires) -- Turtle Beach's ( TBCH ) takeover of Performance Designed Products, or PDP, is going very well and it is expected to generate more than $400 million in total revenue in 2025, Wedbush said in a Friday note. There should be meaningful earnings before interest, taxes, depreciation, and amortization over the next several quarters...
Copyright 2023-2026 - www.financetom.com All Rights Reserved